Enhancing Exposure of Protein Therapeutics
Overview
Authors
Affiliations
Therapeutic proteins have made a major impact on medicine, with significant expansion in the past two decades. The medicinal attributes of these agents, particularly their efficacy and often their safety profile, make protein therapeutics attractive, despite the general necessity of invasive (parenteral) delivery. This perceived hurdle has been a primary component in limiting expansion of this class of drug therapies. Strategies that reduce the frequency of administration directly provide greater convenience to the patient, and potentially greater efficacy, that can yield a significant treatment advantage.:
Miltenburg A, Prohn M, van Kuijk J, Tiessen R, de Kort M, Berg R Br J Clin Pharmacol. 2012; 75(5):1221-30.
PMID: 22978318 PMC: 3635593. DOI: 10.1111/j.1365-2125.2012.04460.x.
Site-specific protein modifications through pyrroline-carboxy-lysine residues.
Ou W, Uno T, Chiu H, Grunewald J, Cellitti S, Crossgrove T Proc Natl Acad Sci U S A. 2011; 108(26):10437-42.
PMID: 21670250 PMC: 3127931. DOI: 10.1073/pnas.1105197108.
Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.
Sola R, Griebenow K BioDrugs. 2010; 24(1):9-21.
PMID: 20055529 PMC: 2805475. DOI: 10.2165/11530550-000000000-00000.
Huet T, Kerbarh O, Schols D, Clayette P, Gauchet C, Dubreucq G Antimicrob Agents Chemother. 2009; 54(1):134-42.
PMID: 19805567 PMC: 2798524. DOI: 10.1128/AAC.00827-09.
Crystal polymorphism of protein GB1 examined by solid-state NMR spectroscopy and X-ray diffraction.
Frericks Schmidt H, Sperling L, Gao Y, Wylie B, Boettcher J, Wilson S J Phys Chem B. 2007; 111(51):14362-9.
PMID: 18052145 PMC: 2774121. DOI: 10.1021/jp075531p.